Abstract
Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Current antagonists against IL-17(A) or its receptor (IL-17RA) that show efficacy in clinical trials are monoclonal antibodies (mAbs). However, recently designed artificial macrocycles are potent IL-17A/IL-17RA antagonists. Based on co-crystal structures, a better understanding of the biological activity and SAR of the macrocycles has been gained, demonstrating that they can compete with mAbs for difficult targets such as PPIs.
| Original language | English |
|---|---|
| Pages (from-to) | 22-26 |
| Number of pages | 5 |
| Journal | MedChemCommun |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan-2018 |
Keywords
- DRUG DISCOVERY
- BINDING-SITE
- T-CELLS
- INTERLEUKIN-17
- RECEPTOR
- INFLAMMATION
- IL-17A
- COMBINATION
- AUTOIMMUNE
- CYTOKINES